π Tomorrow at JSM 2026 "AI-Empowered Decision Making in Drug/Device Development: Benefit, Risk and Mitigation" by ASA BIOP in collaboration with BSLC!
Artificial Intelligence is transforming how we design, conduct, analyze, and interpret clinical research. As AI becomes increasingly integrated into drug and device development, it is equally important to address questions around trust, risk, governance, and responsible implementation.
If you're attending JSM 2026, we encourage you to join this outstanding Late-Breaking Session, sponsored by ASA Biopharmaceutical Section in collaboration with the Biopharmaceutical Statistics Leadership Consortium (BSLC).
π
Tomorrow | Monday, August 3, 2026
π 2:00β3:50 PM
π Room CC-210B, Menino Convention Center, Boston
π― AI-Empowered Decision Making in Drug/Device Development: Benefit, Risk and Mitigation
This distinguished panel brings together leaders from regulatory agencies, academia, and industry, including:
πΉ Robert Califf (Former FDA Commissioner)
πΉ Lisa LaVange (UNC-Chapel Hill)
πΉ Mark van der Laan (UC Berkeley)
πΉ Justine Rochon (Takeda)
πΉ Venkat Sethuraman (Genentech/Roche)
πΉ Mark Levenson (U.S. FDA)
A special thank you to Judy Li, PhD, MBA, FASA and William Wang for organizing what promises to be a timely and thought-provoking discussion.
As AI continues to reshape drug development, conversations like these are essential to ensure we harness its full potential while maintaining scientific rigor, transparency, regulatory confidence, and-most importantly-patient trust.
We look forward to seeing you there!
------------------------------
Hiya Banerjee
Biostatistician
------------------------------